MDB Capital HoldingsMDBH
MDBH
About: MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Employees: 40
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
1.8% less ownership
Funds ownership: 5.11% [Q2] → 3.32% (-1.8%) [Q3]
34% less capital invested
Capital invested by funds: $1.64M [Q2] → $1.08M (-$564K) [Q3]
44% less funds holding
Funds holding: 9 [Q2] → 5 (-4) [Q3]
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for MDBH.
Financial journalist opinion
Neutral
GlobeNewsWire
4 weeks ago
MDB Capital Holdings Provides Third Quarter 2024 Update
Addison, TX, Nov. 21, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today provides an update on operations through and subsequent to the quarter ended September 30, 2024. “Throughout the year, we continued to strengthen our operations to increase our capacity to curate and diligence deep technology ideas that we can ultimately finance and help stand up to become leaders in their technology category,” said Christopher Marlett, CEO and Co-Founder of MDB.
Neutral
GlobeNewsWire
1 month ago
Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
Project is part of the U.S. Department of Defense's BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development Project is part of the U.S. Department of Defense's BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development
Neutral
GlobeNewsWire
1 month ago
MDB Capital Holdings to Host Third Quarter 2024 Results Conference Call on Thursday November 21, 2024, at 4:30 p.m. Eastern Time
Addison, Texas, Nov. 15, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Thursday November 21, 2024 at 4:30 p.m. Eastern Time to discuss its results for the third quarter 2024. A press release detailing these results will be issued prior to the call.
Neutral
GlobeNewsWire
1 month ago
Invizyne Technologies Announces Closing of Initial Public Offering
Monrovia, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the closing of its initial public offering of 1,875,000 shares of its common stock at a public offering price of $8.00 per share. The shares began trading on NASDAQ under the ticker symbol “IZTC” on November 13, 2024.
Neutral
GlobeNewsWire
1 month ago
Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing
Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology
Neutral
GlobeNewsWire
1 month ago
Invizyne Technologies Begins Trading on NASDAQ
Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC" Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
Neutral
GlobeNewsWire
1 month ago
Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024
Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC" Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
Neutral
GlobeNewsWire
1 month ago
Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering
Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC” Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC”
Neutral
GlobeNewsWire
5 months ago
MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies
Record date of July 22, 2024 set for allocation preferences Closing and trading expected on NASDAQ on or before August 15 Addison, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today announces the record date, allocation preference, and expected timeline for the proposed offering for Invizyne Technologies, Inc. In February 2024, Invizyne – a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life and a subsidiary of MDB Capital Holdings – filed its IPO registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") for the sale of its common stock in a firm commitment public offering. The offering will be for 4,300,000 shares of common stock at a price per share of $4.00, for gross proceeds of $17.2 million.
Neutral
GlobeNewsWire
5 months ago
Recently Published Whitepaper from PatentVest Delves into Transformative Innovations in MASH Diagnostics
Transformative Innovations in MASH Diagnostics Dallas, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- PatentVest, the first integrated IP intelligence strategy and law firm, recently published a whitepaper that presents strategic insights in the fields of Metabolic-Associated Steatohepatitis (MASH) biomarkers and Point of Care (PoC) kits for MASH diagnostics. This whitepaper serves as a valuable resource for stakeholders looking to navigate the complex and rapidly evolving landscape of these fields, offering guidance on capitalizing on innovation, collaboration, and IP protection to gain a competitive edge.
Charts implemented using Lightweight Charts™